BACR Annual Meeting 2026

Therapy resistance:
Fundamental and clinical aspects

 


Program          Registration          Abstract          Venue           Sponsors


The online abstract book will become available HERE.
Scientific committee: BACR Board

9:00 Registration, poster mounting & coffee
9:30 – 12:15 MORNING SESSION
Chair: TBD
9:30 Welcome
9:45
Invited speaker 1

Mohamed Bentires-Alj, Université de Bâle, Switzerland
Breast Tumor Heterogeneity and Metastasis: from Mechanistic Insights to Functional Personalized Therapy

10:15
Invited speaker 2

François Lucia, Centre Hospitalier Universitaire de Brest, France
Radiomics-Based Prediction of Radiotherapy and Immunotherapy Resistance Across Lung and Cervical Cancers

10:45 Coffee break & POSTER SESSION 1 (odd numbers)
11:15 Young investigators: oral presentations of 4 selected abstracts

Selected abstract 1

Jorrit De Waele, University of Antwerp

Integrated immune profiling and functional validation support RANKL, TIGIT, and CD47 triple blockade as a cervical cancer-specific immunotherapeutic strategy

Selected abstract 2

Sam Ernst, University of Ghent

Three-dimensional patient-derived tumor fragments enable functional ex vivo profiling of treatment response in solid tumors

Selected abstract 3

Vincent Wuidar, Université de Liège

Shaping ERa activity with pulsed estrogens prevents breast tumor growth and enables safer menopausal hormone therapy

Selected abstract 4

Aurélien Potter, Université Catholique de Louvain

Ferroptosis as a therapeutic vulnerability in TP53-mutated acute myeloid leukemia

12:15 BACR: general assembly (members only)
12:30 – 14:00 LUNCH AND POSTER SESSION 2 (even numbers)
14:00 – 16:45 AFTERNOON SESSION
Chair: TBD
14:00 Young investigators: oral presentations of 4 selected abstracts

Selected abstract 5

Clémence François, Université Catholique de Louvain

Immunospheroid, a 3D framework for the advancement of immunotherapy

Selected abstract 6

Ran Gao, Université de Liège

Tumor-intrinsic mTORC2 signaling reprograms tissue-resident alveolar macrophages to promote immunosuppression and lung cancer progression

Selected abstract 7

Hannah Zaryouh, University of Antwerp

Escaping resistance: EGFR and PI3K co-targeting re-establishes therapeutic response in head and neck cancer

Selected abstract 8

Mikael Olefs, University of Ghent

Disrupting Rab27b-Melanophilin-Dependent Extracellular Vesicle Secretion Impairs DNA Clearance and Promotes Immune Activation in ER-Positive Breast Cancer

15:00 Coffee break
15:30
Invited speaker 3
Nelson Dusetti, Centre de Recherche en Cancérologie Marseille, France
From Predictive Signatures to the Biology of Therapy Resistance in Pancreatic Cancer
16:00
Invited speaker 4
Marie-Julie Nokin, Université de Liège, Belgium
Targeting Metabolic Vulnerabilities in Drug Tolerant BRAF Mutated Lung Cancer
16:30 Awards ceremony for best oral and poster presentations
Concluding remarks
17:00 End of the conference